PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Gerresheimer signs agreement for EUR 325m promissory loan

Duesseldorf, October 08, 2020—Gerresheimer AG has signed a promissory loan agreement for a total of EUR 325m. The transaction with an initial issue amount of EUR 150m was substantially oversubscribed. Consequently, the total amount was increased to EUR 325m.

The promissory loan comprises two equal tranches with terms of three and five years. These feature both fixed and variable interest rates. The transaction is coordinated by Commerzbank, Landesbank Baden-Württemberg and UniCredit.

For the most part, the funds from the loan are being used to repay the five-year tranche under the 2015 promissory loan transcaction.

“The high oversubscription ratio reflects the confidence held by our investors in ourbusiness model and the successful long-term performance of our business,” said Dr.
Bernd Metzner, CFO of Gerresheimer AG. “We are pleased to be able to complete the
refinancing of the maturing promissory loan on even more attractive terms.” Completion
is scheduled for November 10, 2020.


About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products,
the Company contributes to healt h and well-being. Gerresheimer has worldwide operations and around 10,000 employees
manufacture products in local markets close to its customers.

With plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of approximately EUR 1.4bn. Its comprehensive product portfolio includes
pharmaceutical packaging and products for safe and simple drug delivery: insulin pens, inhalers, micro pumps, prefillable
syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems,
as well as packaging for the cosmetics industry.


The annual and interim reports are available here: www.gerresheimer.com/en/investor-relations/reports

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026